Eli Lilly & Co. has been one of the first companies to address the off-label use of their tirzepatide drugs, Mounjaro and Zepbound, for cosmetic weight loss.
Obesity is a chronic disease comprised of dysregulated adipose tissue, increasing the risk of developing serious health conditions, and requires more than just losing weight.